Grateful to @majorajay and all of our colleagues for the support of this work, and excited to share these findings!
A huge congratulations to my mentee Dr. @vpizzuti44 on this analysis of two years of PRO data in CAR-T recipients, now published @BloodPortfolio.
CAR-T confers long-term QoL benefits, and worsening patient-reported fatigue at D+15 may predict subsequent treatment response as a "PRO-marker."
More work to be done to investigate how PRO tools can be used in clinical decision-making. #lymsm #mmsm
sciencedirect.com/science/articl…View quoted post on X
